CERo Therapeutics Holdings, Inc.
CERO · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | $0 | -$0 | -$0 | $1 |
| % Margin | – | – | – | 50% |
| R&D Expenses | $2 | $3 | $3 | $1 |
| G&A Expenses | $2 | $3 | $2 | $1 |
| SG&A Expenses | $2 | $3 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1 | -$0 | $0 |
| Operating Expenses | $4 | $5 | $5 | $2 |
| Operating Income | -$4 | -$5 | -$5 | -$1 |
| % Margin | – | – | – | -103.1% |
| Other Income/Exp. Net | -$7 | -$1 | -$0 | $2 |
| Pre-Tax Income | -$12 | -$5 | -$5 | $1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12 | -$5 | -$5 | $1 |
| % Margin | – | – | – | 107% |
| EPS | -9.1 | -61.71 | -3.18 | 0.56 |
| % Growth | 85.3% | -1,840.6% | -667.9% | – |
| EPS Diluted | -9.1 | -61.71 | -3.18 | 0.56 |
| Weighted Avg Shares Out | 1 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$0 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$5 | -$5 | $2 |
| % Margin | – | – | – | 132.9% |